NCT02827578View on ClinicalTrials.gov

Efficacy and Safety of Tamsulosin/Solifenacin Combination Therapy in Patients With Voiding Symptoms and Moderate to Severe Storage Symptoms Due to Benign Prostate Hyperplasia

PHASE3UnknownINTERVENTIONAL
Enrollment

588

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

August 31, 2017

Study Completion Date

December 31, 2017

Conditions
Benign Prostate Hyperplasia
Interventions
DRUG

Tamsulosin

Tamsulosin

DRUG

Solifenacin

Solifenacin

DRUG

Solifenacin placebo

Solifenacin placebo

Trial Locations (1)

Unknown

RECRUITING

Samsung medical center, Seoul

Sponsors
All Listed Sponsors
lead

IlDong Pharmaceutical Co Ltd

INDUSTRY

NCT02827578 - Efficacy and Safety of Tamsulosin/Solifenacin Combination Therapy in Patients With Voiding Symptoms and Moderate to Severe Storage Symptoms Due to Benign Prostate Hyperplasia | Biotech Hunter | Biotech Hunter